HGF: adverse events in a clinical study
In Ido and colleagues’ open-label study, four patients with severe liver failure received intravenous recombinant HGF for 12–14 days. Blood pressure decreased during infusions in three patients and recovered after administration ended. [1]
This small study in critically ill patients cannot establish adverse-reaction frequencies in broader populations. Its findings do not establish safety of a particular laboratory HGF batch or other routes. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Blood pressure decrease during infusions | Four patients with severe liver failure, intravenous recombinant HGF for 12–14 days | Observed in 3 of 4 patients (75% in this small study; on the pharmacy scale — very common, ≥10%); blood pressure recovered after administration ended | [1] |
References
- Ido A et al. (2011). Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety https://doi.org/10.1186/1479-5876-9-55.